European Respiratory Journal

Article	Citations
The right ventricle tamed	1740
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	1123
Chymase-1: a “MAST”-er switch in COPD?	412
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	328
Missing airways, ventilation defects and conductive airway physiology in asthma	229
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	227
A breath of the future: a novel human model for COPD and beyond	225
The lung that rules the heart	191
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	156
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	149
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	146
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	146
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	144
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	137
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	134
Soteria: deliverance from harm?	132
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	126
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial	122
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	121
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	120
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	117
A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	116
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	116
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	115
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	114

Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	112
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	111
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension	106
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	104
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management	100
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	100
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	97
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	96
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	96
Associations between high-density lipoprotein cholesterol and interstitial lung abnormalities in the Korean national lung cancer screening programme	91
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	90
Reply: Rethinking the optimal cardiac output in pulmonary arterial hypertension	89
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	87
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	83
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	81
Early parenteral prostacyclin therapy enables near-normal haemodynamics and treatment de-escalation in patients with haemodynamically severe pulmonary arterial hypertension	81
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	80
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	78
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	77
A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction	77
Treatment algorithm for pulmonary arterial hypertension	76
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	72
No exposure left behind: time to pay attention to children's chemical environment in lung development	72
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	71
Exciting times for trimodulin	70
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia	68
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	67
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	66
CPAP recall and cancer risk: should we be concerned?	66
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation	65
Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomized controlled trial	64
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	64
FEV1Q: what (even) is normal lung function?	64
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling	64
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	63
End-user global study to identify countries’ challenges and solutions in the uptake and implementation of new tuberculosis treatment regimens	62
The vascular fingerprint of the lungs: why pulmonary vessel count matters in COPD	61
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	61
WHO online guide on the use of digital technologies for tuberculosis programmes	58
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	58
List of European Respiratory Journal peer reviewers 2023	57
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander, et al .	57
Rethinking smoking cessation guidelines in patients with obstructive sleep apnoea: a survey of sleep experts from the ESADA network	56
Pleural mesothelioma: surgery questioned again?	55
Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension	55
Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study	55
The limits of normal of pulmonary arterial wedge pressure	54
Clinical, physiological, imaging and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) study	53
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	52
Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia	52

Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	52
Pulmonary hypertension in patients with Noonan syndrome	51
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	50
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	50
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	48
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	48
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	48
Theratyping in cystic fibrosis: filling the knowledge gaps	47
Inflammatory stimuli and the rescue of disease-causing CFTR nonsense variants	47
Distribution of Blood Eosinophil Count in the Chinese General Population	47
Reading the monocyte code in idiopathic pulmonary fibrosis	47
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	47
Early-life exposure to a mixture of phenols and respiratory health in preschool children	46
COVID-19 changed the world – without changing CTEPH	45
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	45
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	45
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	45
Bronchoconstriction with inhaled ATP in healthy volunteers	44
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	44
Multitasking within the airway epithelium	44
Let's talk about sex… in pulmonary fibrosis	44
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	43
Filters used for pulmonary function testing	43
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	43
ERJ Podcast January 2026: Cannabis and the lung	43
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	42
Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implications	42
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	42
Efficacy and safety of cladribine in adult pulmonary Langerhans cell histiocytosis: a phase II study	41
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	41
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	41
The proteomic landscape of blood monocytes in community-acquired pneumonia	41
Cardiopulmonary response to exercise in adults born very preterm	41
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	41
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	40
ERJ Podcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	40
Oral corticosteroids in asthma and beyond: moving forward	40
ERJ Podcast January 2024: The microbiome in early life and childhood asthma	40
Transcriptomic clustering of critically ill COVID-19 patients	40
Small extracellular vesicles and induction of epithelial-to-mesenchymal transition in lymphangioleiomyomatosis	39
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	39
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	38
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–2002	38
High output heart failure in group 1 pulmonary hypertension and clinical outcomes	38
“Lung function trajectories in South African children with pulmonary tuberculosis compared to those with non-TB lower respiratory tract infection: a prospective study.” D.M. Gray, L. Githinji, K. Brit	38
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	37
Air pollution and COPD: GOLD 2023 committee report	37
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	37
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	37
Reply to: Towards causal validation and clinical translation of the PAK2–fibroblast axis in idiopathic pulmonary fibrosis	36
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	36
Primary spontaneous pneumothorax: does size matter?	36
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	36
Airflow-based prediction of lateral wall collapse: advancing personalised hypoglossal nerve stimulation in obstructive sleep apnoea	36
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	36
Reply to: Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks	36
Fentanyl or Morphine for Persistent Dyspnea in COPD: a multicenter randomised cross-over trial	35
Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD	35
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	35
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	35
Commentary on: Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement	35
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	34
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	34
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	34
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	34
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	33
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	33
Moving the dial on identifying endotypes of asthma from early life	33
Reply: Why fan therapy does not yet demonstrate enhanced training benefits in people with chronic respiratory disease	33
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	33
Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies	33
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	33
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	32
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	32
Relieving dyspnoea through the brain	32
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	32
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	32
Aspergillussensitisation: an underappreciated treatable trait in airway disease	31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	31
Pulmonary hypertension associated with left heart disease	31

Incidence of interstitial lung abnormalities: the MESA Lung Study	31
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	31
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	31
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	30
All roads lead to COPD… or not?	30
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	30
Ensuring availability of respiratory medicines in times of European drug shortages	30
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	30
Beyond phenotypic differences: integrating clinical pharmacy into precision management of paediatric-onset bronchiectasis	29
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	29
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	29
Reply: Addressing unmeasured confounding and detection bias in dupilumab–lymphoma association	29
Reply: SABRE for airway quantification in idiopathic pulmonary fibrosis: clarifications, limitations, and next steps	29
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	29
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	29
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	28
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	28
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	28
Genetic associations between serotonin receptor 1F (HTR1F) regulatory variation and sleep apnoea in non-obese individuals: insights from GWAS and eQTL analyses	28
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	28
Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients	28
ERJ Podcast December 2023: Year in review	27
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flow F ENO	27
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	27
ERJ Podcast July 2023: The HISTORIC study	27
High prevalence of TSC2 mutations in lung tissue samples from patients with sporadic lymphangioleiomyomatosis	27
List of European Respiratory Journal peer reviewers 2022	27
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	27
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	26
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	26
Circulating proteomic landscape of lung function	26
Management of pulmonary hypertension in special conditions	26
Integrating hot topics and implementation of treatable traits in asthma	26
D e novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnoea of infancy	26
Vascular targeted therapies for fibrotic lung disease: start of a new era?	26
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	25
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	25
Progressive pulmonary fibrosis: an expert group consensus statement	25
A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation	25
Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis	25
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	25
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	25
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	25
Clarifying the GOLD 2026 guidance for initial pharmacological COPD treatment	24
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	23
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	23
Heart or lungs? Why not both!	23
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	23
Multi-beat pressure–volume loop-derived right ventricular–pulmonary arterial coupling predicts transplant-free survival in pulmonary arterial hypertension	23
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	23
Drug-induced lung disease: unwanted collateral damage	23
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	23
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	23
The interface in home non-invasive ventilation: is the nasal mask better?	23
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	23
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	23
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline	22
Is two better than one? Targeted treatment of obstructive sleep apnoea using combination therapy to attack endotypes	22
Clinical applications of the 2025 ERS/ATS update of the international multidisciplinary classification of the interstitial pneumonias	22
TB or not TB: does AI have an answer for children?	22
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	21
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	21
Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD	21
Latent COPD: a proposed new term in the disease nomenclature	21
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash, et al . <	21
Life between breaths: quality of life in children's interstitial and diffuse lung disease	21
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study	21
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter, et al . Eur Respir J	21
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	21
Genome-wide association study of susceptibility toPseudomonas aeruginosainfection in cystic fibrosis	21
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	21
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	21
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	20
Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions	20
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis	20
Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial	20
MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease	20
Mycobacterium aviumcomplex genomics and transmission in a London hospital	20
Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts	20
Have we resolved anything yet about sarcoidosis trials?	20
Lungs don't choose neighbourhoods: inequity's toll on breathing	20
The paradox of the safer cigarette: understanding the pulmonary effects of electronic cigarettes	20
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study	20
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept	20
Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis	20
ERJ Podcast April 2026: Use of spirometry to define airflow obstruction and diagnose COPD	20
ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer	20
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors	20
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease, but why were acute exacerbations not considered?	19
Neutrophils in pleural infection: untapped potential for targeted therapeutics	19
From small to big, using microRNA profiling to investigate infant origins of childhood asthma	19
Bronchiectasis in low- and middle-income countries: the importance of the wider view	19
Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension	19
Renal function dynamics in pulmonary hypertension trials: less than anticipated	19